List of publications on a keyword: «триптамины»


Медицина

Publication date: 16.02.2017
Evaluate the material Average score: 3 (Всего: 3)
Mrykhin Vladimir Valerievich , candidate of medical sciences , доцент
FSFEI of HE “Rostov State Medical University” of Russia Ministry of Health , Ростовская обл
Antsyborov Andrey Viktorovich , врач психиатр-нарколог
Medical Center "Mobilnaya medicina" , Ростовская обл

«Psychiatric aspects of designer drugs and new psychoactive substances consumption»

Download an article

According to the authors, appeared not long ago new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, agonists of GABA (A/B) receptors have become a serious problem for both consumers and doctors. Consumers of these substances are attracted primarily by the intensity of psychoactive effects, as well as «legal purity», which is declared by shadow producers. This indicates that there are some significant difficulties of laboratory typing of new surfactants. Designer drugs when ingested, can affect a range of neurotransmitter pathways/receptors: dopamine, cannabinoid (CB1), GABA(A/B), 5-HT2A, glutamate, and k-opioid receptors (KOR), the imbalance of which leads to the development of polymorphic psychotic disorders.